In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 7799337.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess sequential changes of synovial membrane interleukin 1 beta (IL-1 beta) in patients with rheumatoid arthritis receiving chrysotherapy and glucocorticoids. Sequential synovial biopsies taken before and after 2 and 12 weeks of treatment were analyzed by immunohistological techniques. Significant decreases in IL-1 beta staining occurred in biopsies taken after 12 weeks' chrysotherapy, while mononuclear cell numbers were unchanged. Results were similar in patients receiving glucocorticoid and gold, and in those receiving gold alone. These data suggest that chrysotherapy reduces IL-1 beta production in vivo, a property that has been shown in vitro, and that this change precedes changes in synovial membrane mononuclear cell numbers.
Medical subject headings
- Arthritis, Rheumatoid
- Gold Sodium Thiomalate
- Interleukin-1
- Methylprednisolone
- Synovial Membrane